Evidence map›Paper›PMID 39338946›Full record

ReviewPathogens (Basel, Switzerland)2024

Influenza B Virus Vaccine Innovation through Computational Design.

Matthew J Pekarek, Eric A Weaver

Abstract readReview
In one paragraph

Review in Pathogens (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Matthew J PekarekNebraska Center for Virology, School of Biological Sciences, University of Nebraska-Lincoln, Lincoln, NE 68583, USA.ORCID 0000-0003-3214-4220
Eric A WeaverNebraska Center for Virology, School of Biological Sciences, University of Nebraska-Lincoln, Lincoln, NE 68583, USA.ORCID 0000-0002-5029-0662

Funding

Rapid Manufacturing of a Universal Flu Vaccine Using TMV-conjugated Centralized AntigensR01AI147109 · NIAID · UNIVERSITY OF NEBRASKA LINCOLN · PI MCCORMICK, ALISON ANNE, WEAVER, ERIC A · 2020 to 2024
$3.2M
NIAID NIH HHS R01 AI147109NIH HHS 1R01AI147109-04A1
6 · The paper itself

Abstract

As respiratory pathogens, influenza B viruses (IBVs) cause a significant socioeconomic burden each year. Vaccine and antiviral development for influenza viruses has historically viewed IBVs as a secondary concern to influenza A viruses (IAVs) due to their lack of animal reservoirs compared to IAVs. However, prior to the global spread of SARS-CoV-2, the seasonal epidemics caused by IBVs were becoming less predictable and inducing more severe disease, especially in high-risk populations. Globally, researchers have begun to recognize the need for improved prevention strategies for IBVs as a primary concern. This review discusses what is known about IBV evolutionary patterns and the effect of the spread of SARS-CoV-2 on these patterns. We also analyze recent advancements in the development of novel vaccines tested against IBVs, highlighting the promise of computational vaccine design strategies when used to target both IBVs and IAVs and explain why these novel strategies can be employed to improve the effectiveness of IBV vaccines.

Indexed as

Influenza B virusInfluenza, HumanInfluenza VaccinesAnimalsCOVID-19HumansSARS-CoV-2Vaccine DevelopmentInfluenza Vaccinescomputational designimmunogen designinfluenza B virusesSARS-CoV-2surveillancevaccinesviral evolution

Identifiers

PMID39338946
PMCPMC11434669

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.